Alendronate Increases Bone Mass and Reduces Bone Markers in Postmenopausal African-American Women

Abstract

Previous studies indicated that aminobisphosphonate alendronate sodium, a potent inhibitor of bone resorption, increases bone mineral density (BMD) at the hip and spine, reduces markers of bone turnover, and reduces the risk of fractures in Caucasian postmenopausal women. The purpose of the present study was to investigate whether alendronate increases BMD and reduces markers of bone turnover in African-American postmenopausal women. In a multicenter, randomized, double-blind, placebo-controlled study, 65 African-American women, aged 45 to 88 yr, were randomly assigned to either placebo (n = 33) or alendronate 10 mg daily (n = 32) for 2 yr. Mean BMD T scores of the lumbar spine at baseline were −3.18 in the placebo-treated group and −3.09 in the alendronate-treated group. All women took 500 mg elemental calcium daily in the form of calcium carbonate and 500 IU vitamin D. Alendronate significantly increased BMD and reduced markers of bone formation and resorption, compared with placebo. At 2 yr, mean changes ± se in BMD were 6.5% ± 0.7% for the lumbar spine (P < 0.001), 4.5% ± 1.0% for the femoral neck (P < 0.001), 6.4% ± 0.6% for the femoral trochanter (P < 0.001), 4.1% ± 0.7% for the total hip (P < 0.001), 0.7% ± 0.5% for the one third forearm (NS), and 2.0% ± 0.4% for the total body (P < 0.001) in women treated with alendronate, compared with 0.9% ± 0.6% (NS), 0.5% ± 1.1% (NS), −0.2 ± 0.8 (NS), −1.1 ± 0.7% (NS), −0.8% ± 0.6% (NS), and −1.2% ± 0.6% (P < 0.05) for the lumbar spine, femoral neck, trochanter, total hip, one third forearm, and total body, respectively, in women treated with placebo. At 2 yr, mean serum bone-specific alkaline phosphatase had declined by 46.3% with alendronate (P < 0.001) and 13.6% with placebo (P < 0.01), and mean urinary N-telopeptide of type I collagen/creatinine ratio had declined by 70.5% with alendronate (P < 0.001) and 6.7% with placebo (NS). The incidence of adverse experiences was not different between the two groups. We conclude that in postmenopausal African-American women with osteoporosis, alendronate, 10 mg daily for 2 yr, increases BMD at the lumbar spine, hip, and total body and reduces markers of bone remodeling and is well tolerated.